ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
Gross Profit
ANI Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Gross Profit
$305.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
19%
|
CAGR 10-Years
31%
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is ANI Pharmaceuticals Inc's Gross Profit?
Gross Profit
305.3m
USD
Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Gross Profit amounts to 305.3m USD.
What is ANI Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
31%
Over the last year, the Gross Profit growth was 72%. The average annual Gross Profit growth rates for ANI Pharmaceuticals Inc have been 36% over the past three years , 19% over the past five years , and 31% over the past ten years .